IRRITABILITY and Codeine

PatientsVille

Find and Compare Side Effects

IRRITABILITY Symptoms and Causes

For most adults, moderate alcohol use is probably not harmful. However, about 18 million adult Americans have an alcohol use disorder (AUD). This means that their drinking causes distress and harm. It includes alcoholism and alcohol abuse.

Alcoholism, or alcohol dependence, is a disease that causes

Craving - a strong need to drink

Loss of control - not being able to stop drinking once you've started

Physical dependence - withdrawal symptoms

Tolerance - the need to drink more alcohol to feel the same effect

With alcohol abuse, you are not physically dependent, but you still have a serious problem. The drinking may cause problems at home, work, or school. It may cause you to put yourself in dangerous situations, or lead to legal or social problems.

Another common problem is binge drinking. It is drinking about five or more drinks in two hours for men. For women, it is about four or more drinks in two hours.

Too much alcohol is dangerous. Heavy drinking can increase the risk of certain cancers. It can cause damage to the liver, brain, and other organs. Drinking during pregnancy can harm your baby. Alcohol also increases the risk of death from car crashes, injuries, homicide, and suicide.

You may have an AUD if you can answer yes to two or more of these questions:

In the past year, have you

Ended up drinking more or for a longer time than you had planned to?

Wanted to cut down or stop drinking, or tried to, but couldn't?

Spent a lot of your time drinking, or recovering from drinking?

Felt a strong need to drink?

Found that drinking - or being sick from drinking - often interfered with your family life, job, or school?

Kept drinking even though it was causing trouble with your family or friends?

Given up or cut back on activities that you enjoyed just so you could drink?

Gotten into dangerous situations while drinking or after drinking? Some examples are driving drunk and having unsafe sex.

Kept drinking even though it was making you feel depressed or anxious? Or when it was adding to another health problem?

Had to drink more and more to feel the effects of the alcohol?

Had withdrawal symptoms when the alcohol was wearing off? They include trouble sleeping, shakiness, Irritability, anxiety, depression, restlessness, nausea, and sweating. In severe cases, you could have a fever, seizures, or hallucinations.

If you have any of these symptoms, your drinking may already be a cause for concern. The more symptoms you have, the more serious the problem is. If you think you might have an AUD, see your health care provider for an evaluation. Your provider can help make a treatment plan, prescribe medicines, and if needed, give you treatment referrals.

IRRITABILITY Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.

Symptom relief for chronic Irritability in neurologically impaired children using gabapentin.; Prevalence of associated gastrointestinal and sleep problems in neurologically impaired children and improvement using gabapentin.

Primary aim: Collect preliminary data comparing effects of Pregabalin and placebo on abdominal pain/discomfort on bowel symptom score (BSS), overall BSS score, and adequate relief of irritable bowel syndrome (IBS) symptoms in patients with IBS; To compare the effect of Pregabalin and placebo on self-reported overall and individual BSS scores; compare effect of Pregabalin and placebo on adequate relief of IBS pain or discomfort at least 50% of the time; To compare effect of Pregabalin and placebo on overall and individual BSS scores; To compare the effect of Pregabalin and placebo on the proportion of patients with at least 3 point changes in 11 point pain and IBS scores

Change from baseline to Week 6 in KSQ total score; Change from baseline to Week 6 in KSQ anger-hostility subscore; Change from baseline to Week 6 in BIS-11 total score; Change from baseline to Week 6 in AAQ score; Change from baseline to Week 6 in SIS total score; Change from baseline to Week 6 in delay discounting - MCQ scores; Change from baseline to Week 6 in delay discounting - EDT scores; Change from baseline to Week 6 in IDS-C30 total score; Change from baseline to Week 6 in MADRS total score; Change from baseline to Week 6 in MADRS total score in patients with a pre-defined baseline BIS-11 total score; Change from baseline to Week 6 in CPFQ total score; Change from baseline to Week 6 in KSQ depression subscore; Change from baseline to Week 6 in CGI-S score; Change from baseline to Week 6 in CGI-S score in patients with a pre-defined baseline BIS-11 total score; CGI-I score at Week 6; CGI-I score at Week 6 in patients with a pre-defined baseline BIS-11 total score; Change from Week 6 to Week 10 in KSQ anger-hostility subscore; Change from Week 6 to Week 10 in BIS-11 total score; Change from Week 6 to Week 10 in SIS total score; Change from Week 6 to Week 10 in CGI-S score; Change from Week 6 to Week 10 in delay discounting - MCQ scores; Safety; Tolerability; Risk of suicidality

Any Improvement in symptoms of number of bowel habits, urgency, straining,sense of incomplete evacuation, stool form (evaluated by Bristol stool form scale, abdominal pain and bloating/flatulence; Improvement in quality of life in diarrhea dominant IBS by validated IBS-QOL questionnaire.

Weekly response for abdominal pain intensity AND stool consistency over 12 weeks of treatment in at least 50% of the weeks of treatment (6 out of 12 weeks).; Weekly response for abdominal pain intensity over 12 weeks of treatment in at least 50% of the weeks of treatment (6 out of 12 weeks).; Weekly response for stool consistency over 12 weeks of treatment in at least 50% of the weeks of treatment (6 out of 12 weeks).; Weekly Response for relief of overall IBS signs and symptoms over 12 weeks of treatment in at least 50% of the weeks of treatment (6 out of 12 weeks).; Evaluation of rebound effects

Weekly response for abdominal pain intensity AND stool consistency over the first 24 weeks of treatment in at least 50% of the weeks of treatment (12 out of 24 weeks).; Weekly response for abdominal pain intensity over the first 24 weeks of treatment in at least 50% of the weeks of treatment (12 out of 24 weeks).; Weekly response for stool consistency over the first 24 weeks of treatment in at least 50% of the weeks of treatment (12 out of 24 weeks).; Weekly response for relief of overall IBS signs and symptoms over the first 24 weeks of treatment in at least 50% of the weeks (12 out of 24); Sustained efficacy

Severity of bowel symptoms according to the Francis Score; Quality of life; Severity of Anxiety/Depression; Impact of the complementation on fatigue; Impact of the intervention on immunological parameters in stools; Impact of the intervention on immunological parameters in blood; severity of the anxiety/depression

Effect of fecal microbiota transplantation on the symptoms of IBS patients using the IBS version of the gastrointestinal symptom rating scale (GSRS-IBS); Effect of fecal transplantation on IBS patients' visceral perception (Pain scores on the visual analogue scale during barostat procedure); Effect of fecal transplantation on IBS patients' composition of mucosal microbiota (HITChip analysis); Effect of fecal transplantation on IBS patients' composition of fecal microbiota (HITChip analysis); Effect of fecal transplantation on IBS patients' mucosal immune cell composition (lymphocyte fingerprinting using flow cytometry); Effect of fecal microbiota transplantation on the symptoms of IBS patients using the IBS - severity scoring system (IBS-SSS); Effect of fecal microbiota transplantation on the symptoms of IBS patients using the health-related quality of life questionnaire for IBS patients (IBS-QOL); Effect of fecal microbiota transplantation on the symptoms of IBS patients using the hospital and anxiety depression scale (HADS); Effect of fecal microbiota transplantation on the general health of IBS patients using the SF-36 survey

If you think you may have a medical emergency, call your doctor or 911 immediately.

By accessing this website, you are indicating your acknowledgement and acceptance of these Terms of Use. These Terms of Use are subject to change by WinFirst LLC at any time in its discretion. Your use of WinFirst LLC Site after such changes are implemented constitutes your acknowledgement and acceptance of the changes. Please consult these Terms of Use regularly.
PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.